RESUMEN
Anticancer drugs are often associated with limitations such as poor stability in aqueous solutions, limited cell membrane permeability, nonspecific targeting, and irregular drug release when taken orally. One possible solution to these problems is the use of nanocarriers of drug molecules, particularly those with targeting ability, stimuli-responsive properties, and high drug loading capacity. These nanocarriers can improve drug stability, increase cellular uptake, allow specific targeting of cancer cells, and provide controlled drug release. While improving the therapeutic efficacy of cancer drugs, contemporary researchers also aim to reduce their associated side effects, such that cancer patients are offered with a more effective and targeted treatment strategy. Herein, a set of nine porous covalent organic frameworks (COFs) were tested as drug delivery nanocarriers. Among these, paclitaxel loaded in COF-3 was most effective against the proliferation of ovarian cancer cells. This study highlights the emerging potential of COFs in the field of therapeutic drug delivery. Due to their biocompatibility, these porous COFs provide a viable substrate for controlled drug release, making them attractive candidates for improving drug delivery systems. This work also demonstrates the potential of COFs as efficient drug delivery agents, thereby opening up new opportunities in the field of sarcoma therapy.
Asunto(s)
Antineoplásicos , Portadores de Fármacos , Estructuras Metalorgánicas , Neoplasias Ováricas , Paclitaxel , Humanos , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/metabolismo , Portadores de Fármacos/química , Femenino , Antineoplásicos/uso terapéutico , Antineoplásicos/química , Antineoplásicos/farmacología , Paclitaxel/uso terapéutico , Paclitaxel/química , Paclitaxel/farmacología , Estructuras Metalorgánicas/química , Estructuras Metalorgánicas/uso terapéutico , Estructuras Metalorgánicas/farmacología , Línea Celular Tumoral , Porosidad , Liberación de FármacosRESUMEN
With large specific surface area, controllable pore size, increased active sites, and structural stability, two-dimensional metal organic frameworks (2D MOFs) have emerged as promising nanomedicines in cancer therapy. These distinctive features make 2D MOFs particularly advantageous in cancer treatment and the corresponding application has gained considerable popularity, signifying significant application potential. Herein, recent advances in various applications including drug delivery and chemotherapy, photodynamic therapy, sonodynamic therapy, chemodynamic therapy, catalytic therapy, and combined therapy were summarized, with emphasis on the latest progress of new materials and mechanisms for these processes. Moreover, the current challenges, potential solutions, and possible future directions are discussed as well.
Asunto(s)
Antineoplásicos , Estructuras Metalorgánicas , Neoplasias , Estructuras Metalorgánicas/química , Estructuras Metalorgánicas/uso terapéutico , Neoplasias/terapia , Neoplasias/tratamiento farmacológico , Humanos , Antineoplásicos/uso terapéutico , Sistemas de Liberación de Medicamentos/métodos , Fotoquimioterapia/métodos , Nanomedicina/métodos , AnimalesRESUMEN
Addressing the urgent need to prevent breast cancer postoperative recurrence and brain metastasis, Fe-metal organic framework (MOF)-coated hollow mesoporous organosilica nanoparticles (HMON) with tumor microenvironment dual-responsive degradability were prepared to encapsulate doxorubicin (DOX), formulating a tissue-adhesive nanosuspension for perioperative topical medication. This nanosuspension can not only retain the sustainably released drug in the postoperative residual tumor sites but also enhance the intracellular oxidative stress of tumors for remarkable tumor ferroptosis. Interestingly, the nanosuspension can act as an immune amplifier, which could not only stimulate DC cells to secrete chemokines for T cell recruitment but also elevate antigen exposure to facilitate the antigen presentation in lymph nodes. Thus, this nanosuspension could significantly activate antitumor immune responses in both in situ tumors and metastatic encephaloma for enhanced immunotherapy. In conjunction with the clinical PD-1 antibody, the locally administered nanosuspension could achieve an advanced therapeutic outcome for inhibiting postoperative recurrence and metastasis.
Asunto(s)
Neoplasias Encefálicas , Neoplasias de la Mama , Estructuras Metalorgánicas , Nanopartículas , Humanos , Femenino , Neoplasias de la Mama/tratamiento farmacológico , Doxorrubicina/farmacología , Nanopartículas/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Estructuras Metalorgánicas/uso terapéutico , Línea Celular Tumoral , Microambiente TumoralRESUMEN
While performing oxygen-related tumour treatments such as chemotherapy and photodynamic therapy, real-time monitoring hypoxia of tumour is of great value and significance. Here, we design a theranostic combination for light-activated ratiometric hypoxia imaging, hypoxia modulating and prodrug activation. This combination consisted of an oxygen-sensitive near-infrared-emitting ratiometric phosphorescence probe and a hypoxia-activated prodrug-loaded covalent organic framework. In this combination, the probe plays two roles, including quantitative monitoring of oxygen concentration by ratiometric imaging and consuming the oxygen of tumour under light excitation by photodynamic therapy. Meanwhile, the enhanced hypoxia microenvironment of tumour can raise the cytotoxicity of prodrug loaded in covalent organic framework, resulting in boosting antitumour therapeutic effects in vivo. This theranostic combination can precisely provide therapeutic regime and screen hypoxia-activated prodrugs based on real-time tumour hypoxia level, offering a strategy to develop hypoxia mediated tumour theranostics with hypoxia targeted prodrugs.
Asunto(s)
Estructuras Metalorgánicas , Neoplasias , Fotoquimioterapia , Profármacos , Humanos , Medicina de Precisión , Oxígeno , Estructuras Metalorgánicas/uso terapéutico , Neoplasias/diagnóstico por imagen , Neoplasias/tratamiento farmacológico , Hipoxia/tratamiento farmacológico , Profármacos/farmacología , Profármacos/uso terapéutico , Nanomedicina Teranóstica , Línea Celular Tumoral , Fármacos Fotosensibilizantes/uso terapéutico , Microambiente TumoralRESUMEN
Phthalocyanine photosensitizers (PSs) have shown promise in fluorescence imaging and photodynamic therapy (PDT) of malignant tumors, but their practical application is limited by the aggregation-induced quenching (AIQ) and inherent photobleaching of PSs. Herein, we report the synthesis of a two-dimensional nanoscale covalent organic framework (nCOF) with staggered (AB) stacking of zinc-phthalocyanines (ZnPc), ZnPc-PI, for fluorescence imaging and mitochondria-targeted PDT. ZnPc-PI isolates and confines ZnPc PSs in the rigid nCOF to reduce AIQ, improve photostability, enhance cellular uptake, and increase the level of reactive oxygen species (ROS) generation via mitochondrial targeting. ZnPc-PI shows efficient tumor accumulation, which allowed precise tumor imaging and nanoparticle tracking. With high cellular uptake and tumor accumulation, intrinsic mitochondrial targeting, and enhanced ROS generation, ZnPc-PI exhibits potent PDT efficacy with >95% tumor growth inhibition on two murine colon cancer models without causing side effects.
Asunto(s)
Estructuras Metalorgánicas , Neoplasias , Compuestos Organometálicos , Fotoquimioterapia , Compuestos de Zinc , Ratones , Humanos , Animales , Fotoquimioterapia/métodos , Estructuras Metalorgánicas/uso terapéutico , Especies Reactivas de Oxígeno , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/uso terapéutico , Isoindoles , Neoplasias/tratamiento farmacológico , Compuestos Organometálicos/farmacología , Compuestos Organometálicos/uso terapéutico , Indoles/farmacología , Indoles/uso terapéutico , Mitocondrias , Línea Celular TumoralRESUMEN
A new microporous lanthanide metal-organic framework, {[Yb(BTB)(H2O) (DEF)2}n (1, DEF=N,N-Diethylformamide), with 1D nano-sized channels has been constructed by bridging helical chain secondary building units with 1,3,5-benzenetrisbenzoic acid (H3BTB) ligand. Structural characterization suggests that this complex crystallizes in the hexagonal space group P6122 and possesses 1D triangular channels with coordinated water molecules pointing to the channel center. In addition, anti-myocarditis properties of compound 1 were evaluated in vivo. The results showed that compound 1 can improve hemodynamic parameters of, and it may be a good therapeutic option for heart failure in the future.